We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Speeds Review of Remdesivir for Conditional Authorization
EMA Speeds Review of Remdesivir for Conditional Authorization
The European Medicines Agency (EMA) said it is giving a fast-track review to a conditional marketing authorization request from Gilead Sciences for using remdesivir to treat COVID-19 patients.